Precipio, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Precipio reported Q2-2026 revenue of $7.0M (up 22% YoY from $5.7M in Q2-2025), comprising $6.1M pathology and $0.9M product revenue. Adjusted EBITDA turned positive at $0.4M versus negative $0.2M in Q1-2026, driven by $0.3M revenue increase and $0.2M reduction in stock-based compensation. Cash position strengthened to over $3M (from $1.1M in Q2-2025) via $0.7M operating cash flow, achieved without new financing.
Why this rating
For a $15.2M market-cap company, achieving profitability inflection, 22% YoY growth, and tripling cash to $3M is operationally significant and validates the business model turnaround, but execution risk remains high.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.